Several studies have already shown that early virologic response predicts sustained virologic response in patients infected with only HCV, Dr. Montserrat Laguno from Hospital Clinic Universitari de Barcelona, and associates explain. But it is unclear whether this holds true in patients co-infected with HIV and HCV.

Dr. Laguno's group investigated the utility of an early virologic response to predict a sustained virologic response to HCV therapy in 95 co-infected patients.

Early virologic response was associated with a sustained virologic response, with a positive predictive value of 64%, the authors report in the February 1st issue of the Journal of Acquired Immune Deficiency Syndromes. In contrast, none of the patients without an early virologic response had a sustained virologic response, the report indicates.

Achieving undetectable HCV RNA at week 4 (a very early virologic response) predicted sustained virologic response with a positive predictive value of 89% and a negative predictive value of 70%, the researchers note.

A very early virologic response had higher positive predictive value for sustained virologic response when patients received pegylated interferon as opposed to interferon, the results indicate.

"The results of our study suggest that the rules of reduction of 2 log of the viral load at week 12 of HCV therapy in co-infected patients have the same value as those in mono-infected patients," the investigators conclude.

J Acquir Immune Defic Syndr 2007;44:174-178.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.